These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
404 related articles for article (PubMed ID: 11606503)
1. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Mitchell SA; Bansi DS; Hunt N; Von Bergmann K; Fleming KA; Chapman RW Gastroenterology; 2001 Oct; 121(4):900-7. PubMed ID: 11606503 [TBL] [Abstract][Full Text] [Related]
2. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Lindor KD; Kowdley KV; Luketic VA; Harrison ME; McCashland T; Befeler AS; Harnois D; Jorgensen R; Petz J; Keach J; Mooney J; Sargeant C; Braaten J; Bernard T; King D; Miceli E; Schmoll J; Hoskin T; Thapa P; Enders F Hepatology; 2009 Sep; 50(3):808-14. PubMed ID: 19585548 [TBL] [Abstract][Full Text] [Related]
3. Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses. van Hoogstraten HJ; Wolfhagen FH; van de Meeberg PC; Kuiper H; Nix GA; Becx MC; Hoek AC; van Houte DP; Rijk MC; Salemans JM; Scherpenisse J; Schrijver M; Smit AM; Spoelstra P; Stadhouders PH; Tan TG; Hop WC; ten Kate FJ; vanBerge-Henegouwen GP; Schalm SW; van Buuren HR J Hepatol; 1998 Sep; 29(3):417-23. PubMed ID: 9764988 [TBL] [Abstract][Full Text] [Related]
4. [Treatment of cholestatic liver diseases with ursodeoxycholic acid]. Boberg KM; Schrumpf E Tidsskr Nor Laegeforen; 1997 Sep; 117(23):3370-3. PubMed ID: 9411890 [TBL] [Abstract][Full Text] [Related]
5. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Smith T; Befeler AS Curr Gastroenterol Rep; 2007 Mar; 9(1):54-9. PubMed ID: 17335678 [TBL] [Abstract][Full Text] [Related]
6. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. Färkkilä M; Karvonen AL; Nurmi H; Nuutinen H; Taavitsainen M; Pikkarainen P; Kärkkäinen P Hepatology; 2004 Dec; 40(6):1379-86. PubMed ID: 15565569 [TBL] [Abstract][Full Text] [Related]
7. Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response. van de Meeberg PC; Wolfhagen FH; Van Berge-Henegouwen GP; Salemans JM; Tangerman A; van Buuren HR; van Hattum J; van Erpecum KJ J Hepatol; 1996 Dec; 25(6):887-94. PubMed ID: 9007717 [TBL] [Abstract][Full Text] [Related]
8. Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience. Lemoinne S; Pares A; Reig A; Ben Belkacem K; Kemgang Fankem AD; Gaouar F; Poupon R; Housset C; Corpechot C; Chazouillères O Clin Res Hepatol Gastroenterol; 2018 Dec; 42(6):521-528. PubMed ID: 30100231 [TBL] [Abstract][Full Text] [Related]
9. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis. Wunsch E; Trottier J; Milkiewicz M; Raszeja-Wyszomirska J; Hirschfield GM; Barbier O; Milkiewicz P Hepatology; 2014 Sep; 60(3):931-40. PubMed ID: 24519384 [TBL] [Abstract][Full Text] [Related]
10. Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis. Lindström L; Hultcrantz R; Boberg KM; Friis-Liby I; Bergquist A Clin Gastroenterol Hepatol; 2013 Jul; 11(7):841-6. PubMed ID: 23353641 [TBL] [Abstract][Full Text] [Related]
11. Does ursodeoxycholic acid mediate immunomodulatory and anti-inflammatory effects in patients with primary sclerosing cholangitis? van Milligen de Wit AW; Kuiper H; Camoglio L; van Bracht J; Jones EA; Tytgat GN; van Deventer SJ Eur J Gastroenterol Hepatol; 1999 Feb; 11(2):129-36. PubMed ID: 10102223 [TBL] [Abstract][Full Text] [Related]
13. Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC Study Group. van Hoogstraten HJ; Vleggaar FP; Boland GJ; van Steenbergen W; Griffioen P; Hop WC; van Hattum J; van Berge Henegouwen GP; Schalm SW; van Buuren HR Am J Gastroenterol; 2000 Aug; 95(8):2015-22. PubMed ID: 10950051 [TBL] [Abstract][Full Text] [Related]
14. Urosdeoxycholic acid in primary sclerosing cholangitis: a meta-analysis and systematic review. Othman MO; Dunkelberg J; Roy PK Arab J Gastroenterol; 2012 Sep; 13(3):103-10. PubMed ID: 23122450 [TBL] [Abstract][Full Text] [Related]
15. Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis. Holtmeier J; Leuschner U Digestion; 2001; 64(3):137-50. PubMed ID: 11786661 [TBL] [Abstract][Full Text] [Related]
16. A prospective, randomized-controlled pilot study of ursodeoxycholic acid combined with mycophenolate mofetil in the treatment of primary sclerosing cholangitis. Sterling RK; Salvatori JJ; Luketic VA; Sanyal AJ; Fulcher AS; Stravitz RT; Contos MJ; Mills AS; Shiffman ML Aliment Pharmacol Ther; 2004 Nov; 20(9):943-9. PubMed ID: 15521841 [TBL] [Abstract][Full Text] [Related]
17. Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression. Sinakos E; Marschall HU; Kowdley KV; Befeler A; Keach J; Lindor K Hepatology; 2010 Jul; 52(1):197-203. PubMed ID: 20564380 [TBL] [Abstract][Full Text] [Related]
18. Management of cholestatic disease in 2017. de Vries E; Beuers U Liver Int; 2017 Jan; 37 Suppl 1():123-129. PubMed ID: 28052628 [TBL] [Abstract][Full Text] [Related]
19. Bile acids for primary sclerosing cholangitis. Poropat G; Giljaca V; Stimac D; Gluud C Cochrane Database Syst Rev; 2011 Jan; 2011(1):CD003626. PubMed ID: 21249655 [TBL] [Abstract][Full Text] [Related]